OncoCyte is a diagnostics & research business based in the US. OncoCyte shares (OCX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.03 – a decrease of 6.06% over the previous week. OncoCyte employs 46 staff and has a trailing 12-month revenue of around $1.9 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $3.03 |
|---|---|
| 52-week range | $1.92 - $4.75 |
| 50-day moving average | $3.10 |
| 200-day moving average | $2.85 |
| Wall St. target price | $4.42 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-4.66 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.025 from 2025-05-02
| 1 week (2025-04-25) | -12.06% |
|---|---|
| 1 month (2025-04-04) | 9.21% |
| 3 months (2025-02-05) | 40.05% |
| 6 months (2024-11-05) | 3.60% |
| 1 year (2024-05-03) | 13.72% |
|---|---|
| 2 years (2023-05-04) | -43.61% |
| 3 years (2022-05-04) | 24.2 |
| 5 years (2020-05-04) | 53.8 |
| Revenue TTM | $1.9 million |
|---|---|
| Gross profit TTM | $828,000 |
| Return on assets TTM | -26.42% |
| Return on equity TTM | -910.86% |
| Profit margin | 0% |
| Book value | $-0.70 |
| Market Capitalization | $98.4 million |
TTM: trailing 12 months
We're not expecting OncoCyte to pay a dividend over the next 12 months.
OncoCyte's shares were split on a 1:20 basis on 24 July 2023 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your OncoCyte shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for OncoCyte shares which in turn could have impacted OncoCyte's share price.
Over the last 12 months, OncoCyte's shares have ranged in value from as little as $1.922 up to $4.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while OncoCyte's is 0.976. This would suggest that OncoCyte's shares are less volatile than average (for this exchange).
OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents.
Track the progress of the S&P 500 stocks to make more informed investment decisions.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Compare pros, cons, research tools and reviews for these two trading platforms.
Some of the best trading apps like Robinhood are SoFi, Tastytrade, Public, eToro, Acorns, Interactive Brokers, E*TRADE and more.
Compare pros, cons, research tools and reviews for these two trading platforms.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.